Registration for a live webinar on 'Rare disease clinical trials: challenges and best practices' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Agenda
- "Severe asthma" first definition
- "Difficult asthma" ERS taskforce definition
- "Refractory asthma" ATS criteria
- Revised GINA definition of severe asthma
- Heterogeneous reasons for severe asthma
- Reasons for asthma symptoms variety
- "High dose" therapy
- Definition summary
- Treatments for severe asthma?
- Inflammation type
- Sinonasal polyposis
- Effect of CRS treatment on asthma
- Inflammation in distal airways in severe asthma
- Extra-fine ICS effect on large and small airways
- Extra-fine ICS effect on asthma exacerbations
- Intense and medical resistant inflammation
- Consistency of sputum eosinophilia over time
- Allergic vs. intrinsic asthma
- Mechanism of action of anti IgE
- Effect of anti IgE on severe asthma exacerbations
- "Intrinsic" asthma
- Systemic steroids in 'refractory' eosinophilia
- Anti IL-5 effect
- Treatment with oral steroids and anti-IL-5
- No eosinophilic inflammation
- Clarithromycin in neutrophilic asthma
- Macrolides in chronic stable asthma
- Asthma and obesity
- Asthma mechanism in obese patients
- Weight reduction improves asthma
- Effect of bariatric surgery on asthma severity
- Down-titrating oral corticosteroids
- Obese patients asthma summary
- Eosinophilic inflammation summary
- No eosinophilic inflammation summary
- Implications for the future
- "Electronic nose"
- U-BIOPRED
Topics Covered
- Difficult asthma and severe refractory asthma
- Heterogeneous reasons for severe asthma
- "High dose" therapy
- Treatments for severe asthma
- Eosinophilic vs. non eosinophilic inflammation
- Effect of CRS treatment on asthma
- Mechanism of action of anti IgE
- Effect of anti IgE on severe asthma exacerbations
- Effect of anti IL-5 (mepolizumab) on spontaneous asthma exacerbations
- Clarithromycin in neutrophilic asthma
- Macrolides in chronic stable asthma
- Mechanisms of asthma severity in obese patients
- Implications for the future
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Bel, E. (2011, December 29). Management of "difficult asthma" [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 16, 2024, from https://doi.org/10.69645/FVXN4274.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Elisabeth Bel, Grant/Research Support (Principal Investigator): unrestricted grant for department from GSK (60,000 EURO), Novartis (16,000 EURO)